1. Academic Validation
  2. Synthesis of Structural ADP-Ribose Analogues as Inhibitors for SARS-CoV-2 Macrodomain 1

Synthesis of Structural ADP-Ribose Analogues as Inhibitors for SARS-CoV-2 Macrodomain 1

  • Org Lett. 2024 Jul 12;26(27):5700-5704. doi: 10.1021/acs.orglett.4c01792.
Koen J Rijpkema 1 Marion Schuller 2 Miriam S van der Veer 1 Sjoerd Rieken 1 Diego L R Chang 1 Pascal Balić 1 Alex Todorov 1 Hugo Minnee 1 Sven Wijngaarden 1 Isaac A Matos 2 3 Nicolas C Hoch 3 Jeroen D C Codée 1 Ivan Ahel 2 Dmitri V Filippov 1
Affiliations

Affiliations

  • 1 Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
  • 2 Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom.
  • 3 Departamento de Bioquímica, Instituto de Química, Universidade de Sao Paulo, Av. Prof. Lineu Prestes, 748, Cidade Universitária, Sao Paulo 055800-000, Brasil.
Abstract

Protein adenosine diphosphate (ADP)-ribosylation is crucial for a proper immune response. Accordingly, viruses have evolved ADP-ribosyl hydrolases to remove these modifications, a prominent example being the SARS-CoV-2 NSP3 macrodomain, "Mac1". Consequently, inhibitors are developed by testing large libraries of small molecule candidates, with considerable success. However, a relatively underexplored angle in design pertains to the synthesis of structural substrate mimics. Here, we present the synthesis and biophysical activity of novel adenosine diphosphate ribose (ADPr) analogues as SARS-CoV-2 NSP3 Mac1 inhibitors.

Figures
Products